Experimental Alzheimer’s drug shows promise, but there are many hurdles still to overcome

Cloud technology with futuristic hologram on smartwatch

The first drug that can slow the rate of decline in Alzheimer’s patients has been found. The experimental drug, called lecanemab, is an antibody that targets the toxic clumps of amyloid protein associated with the mind-robbing disease. While these results are cause for celebration, there are still significant questions about its safety and rollout.

Grab the Instant Stand Mixer Pro for its lowest price ever

Previous article

Pandemic exacerbated disparities in postpartum care

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations